Compare EW & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EW | NTRA |
|---|---|---|
| Founded | 1958 | 2003 |
| Country | United States | United States |
| Employees | 16000 | N/A |
| Industry | Industrial Specialties | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.3B | 56.7B |
| IPO Year | 1999 | 2015 |
| Metric | EW | NTRA |
|---|---|---|
| Price | $90.30 | $402.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 30 | 23 |
| Target Price | $101.39 | ★ $411.39 |
| AVG Volume (30 Days) | ★ 3.1M | 1.4M |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.65 |
| EPS | ★ 1.07 | N/A |
| Revenue | ★ $6,067,600,000.00 | $210,939,000.00 |
| Revenue This Year | $11.42 | $26.20 |
| Revenue Next Year | $9.91 | $20.84 |
| P/E Ratio | $83.43 | ★ N/A |
| Revenue Growth | ★ 11.55 | N/A |
| 52 Week Low | $74.66 | $181.00 |
| 52 Week High | $96.29 | $437.41 |
| Indicator | EW | NTRA |
|---|---|---|
| Relative Strength Index (RSI) | 60.19 | 56.87 |
| Support Level | $82.21 | $380.39 |
| Resistance Level | $93.43 | $437.41 |
| Average True Range (ATR) | 2.02 | 16.45 |
| MACD | 0.56 | -2.59 |
| Stochastic Oscillator | 93.62 | 58.34 |
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.